Investment Rating - The report upgrades the investment rating to "Buy" with a target price not specified [5] Core Viewpoints - The company reported a revenue of 2.51 billion RMB for 2024, a decrease of 2.8% year-on-year, and a net profit of 181 million RMB, down 12.6% year-on-year [1] - Direct sales accounted for 87% of total sales in 2024, an increase of 9 percentage points year-on-year, with revenue growth in the Asia-Pacific, Europe, Middle East, and Africa regions [2] - The company has received EU medical device certification, marking a significant step towards full product line certification, and has launched three core products in new markets [3] - The company is expanding its product range in the injection filling business, including new products and exclusive distribution agreements [4] - Revenue projections for 2025-2027 are 3.03 billion, 3.56 billion, and 3.81 billion RMB respectively, with net profits of 285 million, 345 million, and 391 million RMB [5] Summary by Sections Financial Performance - 2024 revenue was 2.51 billion RMB, down 2.8% year-on-year; net profit was 181 million RMB, down 12.6% year-on-year [1] Sales Strategy - Direct sales strategy led to an 87% sales contribution in 2024, with regional revenue growth in Asia-Pacific (6.0%), Europe (0.7%), and the Middle East and Africa (27.1%), while North America saw a decline of 12.4% [2] Product Development - The company achieved EU medical device certification and launched three innovative products, including Alma Harmony™, Soprano Titanium™, and Alma IQ™, which received high market recognition [3] Market Expansion - The company is actively expanding its injection filling product line, including the launch of Profhilo® in China and Thailand, and exclusive distribution rights for Revanesse® in key markets [4] Future Projections - Expected revenues for 2025-2027 are 3.03 billion, 3.56 billion, and 3.81 billion RMB, with net profits projected at 285 million, 345 million, and 391 million RMB [5]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for the stock price over the next six months [6]. Core Insights - The company reported a revenue of HKD 1.913 billion for 2024, a slight decrease of 0.56% year-on-year, with a net loss attributable to shareholders of HKD 135 million, compared to a profit in the previous year [1][2]. - The gross margin decreased to 27.58%, down 4.59 percentage points year-on-year, primarily due to price reductions in ophthalmic surgeries and an increase in low-margin dental services [2]. - The company is focusing on expanding its dental business, which saw a revenue increase of 18.50% to HKD 507 million, driven by the mainland's healthcare policies [3][4]. - The company is undergoing a restructuring phase in 2024, with plans to close underperforming facilities while expanding its presence in the Greater Bay Area [4]. Financial Summary - The company expects revenues to grow to HKD 2.179 billion in 2025, with a projected net profit of HKD 75 million, reflecting a significant recovery from the current year's losses [5][10]. - The projected PE ratios for 2025, 2026, and 2027 are 26X, 21X, and 18X respectively, indicating a gradual improvement in profitability [4][10]. - The report highlights a projected gross margin recovery to 30.9% by 2025, suggesting improved operational efficiency [10].

Investment Rating - The report gives a "Buy" rating for the company, Mijue Group (2097.HK) [1] Core Insights - Mijue Group has established itself as a leading player in the tea beverage industry in China, with over 45,000 stores across 11 countries as of Q3 2024, achieving a revenue of 18.66 billion yuan [2][11] - The ready-to-drink beverage market is experiencing rapid growth, with China's market expected to grow from 517.5 billion yuan in 2023 to 1,163.4 billion yuan by 2028, reflecting a compound annual growth rate (CAGR) of 11.59% [2][37] - The company benefits from a strong supply chain and economies of scale, with a low entry barrier for franchisees and a robust support system for franchisees, leading to rapid store expansion [2][20] Summary by Sections Company Overview - Founded in 1997, Mijue Group has evolved from a street vendor to a global beverage giant, with significant milestones including the establishment of a central factory and a logistics system [4][20] - The company operates two main brands: Mijue Ice City for tea beverages and Lucky Coffee for coffee, with a focus on affordable pricing [20][18] Financial Performance - The company reported revenues of 10.35 billion yuan, 13.58 billion yuan, and 20.3 billion yuan for the years 2021, 2022, and 2023 respectively, with a continuous growth rate exceeding 20% [11] - For the forecasted years 2024 to 2026, revenues are expected to reach 24.82 billion yuan, 30.16 billion yuan, and 33.91 billion yuan, with corresponding net profits of 4.58 billion yuan, 5.63 billion yuan, and 6.40 billion yuan [2] Market Dynamics - The global ready-to-drink beverage market is projected to grow significantly, with the share of ready-to-drink beverages increasing due to their freshness and health benefits compared to bottled drinks [33][34] - The Chinese market, particularly in lower-tier cities, presents substantial growth opportunities, with a projected CAGR of 22.18% for affordable ready-to-drink beverages from 2023 to 2028 [37][40] Competitive Advantages - Mijue Group has established a comprehensive supply chain that includes procurement, production, logistics, and warehousing, which helps stabilize raw material prices and reduce costs [55][63] - The company employs a low-cost franchise model, allowing for rapid expansion and strong profitability for franchisees, with a focus on high-density locations in lower-tier cities [44][51]

证券研究报告 公用事业 | 电力 港股|公司点评报告 hyzqdatemark 2025 年 03 月 25 日 证券分析师 查浩 SAC：S1350524060004 zhahao@huayuanstock.com 刘晓宁 SAC：S1350523120003 liuxiaoning@huayuanstock.com 邓思平 SAC：S1350524070003 dengsiping@huayuanstock.com 市场表现： | 基本数据 | 2025 | 年 | 03 | 月 24 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 3.00 | | | 一年内最高/最低（港 | | | | 4.27/2.81 | | | 元） | | | | | | | 总市值（百万港元） | | | | 37,110.45 | | | 流通市值（百万港元） | | | | 37,110.45 | | | 资产负债率（%） | | | | 68.42 | | | 资料来源：聚源数据 | | | | | | 中国电力(02380.HK) 投资评级 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is entering a sustainable profit phase, with positive earnings guidance for 2025 [5] - The company reported a net profit of $37.7 million for 2024, exceeding expectations, indicating financial self-sufficiency [7] - The core product, furmonertinib, has exceeded market expectations in global sales, and the company is expanding its pipeline with tangible progress [7] - The company has a strong cash position of $836.1 million as of the end of 2024, supporting future drug development [7] - The 2025 revenue guidance for the oncology/immunology business is set between $350 million and $450 million, driven by continued growth in furmonertinib sales [7] Financial Performance and Forecast - Revenue for 2023 is projected at $838 million, with a significant decline of 24.8% in 2024, followed by a recovery to $694 million in 2025, and further growth to $844 million in 2026 and $996 million in 2027 [6][11] - The net profit is expected to rebound dramatically from $38 million in 2024 to $393 million in 2025, reflecting a growth rate of 942.79% [6][11] - The company’s earnings per share (EPS) is forecasted to increase from $0.04 in 2024 to $0.45 in 2025 [6][11] - The return on equity (ROE) is expected to rise significantly to 34.2% in 2025 [6] Company Events and Future Catalysts - The company plans to submit a New Drug Application (NDA) for savolitinib in the second-line NSCLC indication in 2025, with promising clinical data [7] - The company is advancing its antibody-drug conjugate (ATTC) platform, which is expected to start clinical trials in the second half of 2025 [7] - The company has a diversified and validated late-stage product pipeline, with several drugs expected to receive regulatory approvals in China [8]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [3][7]. Core Insights - The company achieved a revenue of 12.261 billion CNY in 2024, representing a year-on-year growth of 21.3%, and a profit of 4.372 billion CNY, up 33.4% year-on-year [1][2]. - The sales revenue from innovative drugs and collaborative products reached 9.477 billion CNY in 2024, a 38.1% increase, accounting for 77.3% of total revenue [7]. - The company has shown strong cost control, with a gross margin of 91% in 2024, an increase of 1.2 percentage points year-on-year [7]. - The company is actively pursuing global collaborations, enhancing its competitive edge, with significant partnerships established in 2024 [7]. Financial Data and Valuation - The company’s projected revenues for 2025-2027 are 13.714 billion CNY, 15.395 billion CNY, and 17.378 billion CNY, with respective year-on-year growth rates of 12%, 12%, and 13% [2][9]. - The projected net profits for 2025-2027 are 4.588 billion CNY, 5.152 billion CNY, and 5.930 billion CNY, with growth rates of 5%, 12%, and 15% respectively [7][9]. - The company’s PE ratios for 2025-2027 are projected to be 24.6, 21.9, and 19.1 [9]. Shareholder Information - The total market capitalization of the company is 120.5 billion HKD, with a total share capital of 5,936 million shares [3]. - The major shareholder, Sunrise Investment Advisors Limited, holds a 65.7% stake in the company [3]. Performance Metrics - The company’s return on equity (ROE) is reported at 15.2% for 2024, with a projected increase to 15.4% by 2027 [9]. - The asset-liability ratio is notably low at 9.4% in 2024, indicating strong financial stability [9].

Investment Rating - The investment rating for the company is "Buy" [2][8] Core Views - The education industry remains buoyant, with the company experiencing significant revenue growth in 2024 and further potential for growth in 2025 [3][8] - The company has shown a remarkable increase in contract liabilities, indicating strong pre-sales in its quality education segment [8] Financial Summary - Revenue for 2024 is projected at 11.02 billion RMB, representing a year-on-year increase of 125.2% [8] - Gross profit for 2024 is expected to be 5.10 billion RMB, up 121.9% year-on-year [8] - Net profit for 2024 is forecasted at 1.92 billion RMB, reflecting a 114% increase compared to the previous year [8] - The company’s gross margin for 2024 is estimated at 46.3%, slightly down by 0.6 percentage points year-on-year [8] - Contract liabilities reached 6.02 billion RMB, a significant increase of 184.27% year-on-year, primarily driven by prepayments in the quality education business [8] Business Segmentation - Revenue from quality education in 2024 is expected to be 7.13 billion RMB, a substantial increase of 411.75% year-on-year [8] - Full-time education revenue is projected at 2.07 billion RMB, with a modest growth of 0.98% year-on-year [8] - Tutoring project revenue is anticipated to be 1.81 billion RMB, reflecting a year-on-year increase of 25.20% [8] Market Position and Technology Integration - The company is expected to enhance its market share in the Guangzhou and Shenzhen markets, supported by AI applications that improve operational efficiency [8] - The integration of AI into the company's educational systems aims to provide personalized learning experiences and improve teaching effectiveness [8]

Investment Rating - The investment rating for the company is "Buy" [7][19]. Core Insights - The adjusted net profit exceeded Bloomberg consensus expectations, with significant improvement in core OTA profitability [2][3]. - In Q4 2024, the company achieved revenue of 4.24 billion yuan, a year-on-year increase of 34.8%, and an adjusted net profit of 660 million yuan, up 36.8% year-on-year, with a net profit margin of 15.6% [3]. - The core OTA business showed a notable improvement in operating profit margin, which increased by 6.8 percentage points to 28.4% year-on-year [3][5]. Revenue Breakdown - The transportation business generated revenue of 1.72 billion yuan, a year-on-year increase of 17.0%, with international ticket market share expanding rapidly, and annual business volume growing over 130% [5]. - Accommodation business revenue reached 1.14 billion yuan, up 28.6% year-on-year, with international hotel business maintaining industry-leading growth, and annual business volume increasing over 110% [5]. - Other business revenue was 600 million yuan, a year-on-year increase of 14.8%, with the Yilong hotel technology platform expanding to nearly 2,300 hotels [5]. - Vacation business revenue was 780 million yuan, driven by product and service value, supporting over 1,000 travel agency stores [5]. User Metrics - The average monthly paying user count reached a historical high of 43.1 million, up 4.4% year-on-year, with an annual paying user count of 240 million, an increase of 1.5% [6]. - The total service user count for the year reached 1.93 billion, a year-on-year increase of 9.3% [6]. Profit Forecast and Investment Suggestion - The company is positioned as a leading OTA in the lower-tier market, benefiting from Tencent and Ctrip's traffic and inventory resources, with competitive advantages in domestic business and active international market expansion [7]. - The adjusted net profit forecast for 2025-2027 is raised to 3.4 billion, 4.0 billion, and 4.7 billion yuan respectively, with corresponding P/E ratios of 13, 11, and 9 times [7].

Investment Rating - The report assigns a "Buy" rating for the company, Conant Optical (02276.HK) [1] Core Insights - The company's revenue is expected to grow significantly from 2024 to 2026, with projected revenues of 20.6 billion, 23.7 billion, and 27.5 billion RMB, representing year-on-year growth rates of 16.9%, 15.1%, and 16.3% respectively [6] - The net profit is forecasted to increase to 4.3 billion, 5.7 billion, and 6.9 billion RMB for the same period, with corresponding year-on-year growth rates of 32.2%, 31.4%, and 21.4% [6] - The company is positioned as a leading supplier of resin lenses, focusing on high-value customized and high-refractive lenses, which are expected to enhance profitability [7][8] - The report highlights the company's strategic partnerships with leading global consumer electronics firms to capitalize on the XR (Extended Reality) industry, which is anticipated to drive future growth [8] Summary by Sections Company Overview - Conant Optical is a leading provider of resin eyeglass lenses, focusing on both standardized and high-end customized lenses [15] - The company has undergone restructuring to concentrate on its resin lens business, enhancing operational efficiency [15] Financial Performance - The company achieved a revenue of 1.76 billion RMB in 2023, with a year-on-year growth of 12.7% [9] - The gross margin has improved from 33% in 2019 to 39% in the first half of 2024, driven by an increase in the proportion of customized and high-refractive lenses [31] Market Trends - The global eyeglass lens manufacturing market is projected to grow at a compound annual growth rate (CAGR) of approximately 5.6% from 2023 to 2028 [7][45] - The demand for high-refractive lenses is expected to rise as consumer preferences shift towards lighter and thinner lenses [42] XR Industry Engagement - The company has established an XR R&D service center and is collaborating with several leading consumer electronics companies on various projects [8][65] - A new automated production line for XR-compatible lenses is planned to be built in Thailand, indicating the company's commitment to expanding its capabilities in this emerging market [8][65]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [5]. Core Insights - The company reported a revenue of 850 million RMB for 2024, representing a 49% year-on-year increase, and a net profit of 176 million RMB, which is a 63% increase [1]. - The growth in revenue is attributed to an increase in tutoring hours and operational efficiency improvements [1][2]. - The company is expanding its business in Guangzhou and has launched new educational tourism and international courses, aiming to diversify its revenue streams [2]. - Future revenue projections for 2025-2027 are adjusted to 1.18 billion RMB, 1.61 billion RMB, and 2.19 billion RMB respectively, with net profits expected to be 236 million RMB, 321 million RMB, and 433 million RMB [3]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 850 million RMB, with non-academic courses contributing 770 million RMB, and tutoring course revenue reaching 86 million RMB [1]. - The number of enrolled students increased to 350,000, with tutoring course hours totaling 8.69 million [1]. Business Development - The company is actively working on re-establishing its presence in the Guangzhou market, which has shown positive initial results [2]. - It aims to enhance its service offerings in various educational areas, including arts, sports, and logic training, to support balanced development for students [2]. Future Outlook - The company plans to leverage its brand influence and management expertise to explore new opportunities and expand its revenue base [2]. - Cost control measures will be strictly implemented to maintain healthy cash flow while enhancing service quality through technology and AI [2].